

# Jonathan Sive

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3062462/publications.pdf>

Version: 2024-02-01

8  
papers

69  
citations

1683354  
5  
h-index

1719596  
7  
g-index

8  
all docs

8  
docs citations

8  
times ranked

147  
citing authors

#	ARTICLE	IF	CITATIONS
1	Patients with plasma cell disorders undergoing autologous stem cell transplant retain their humoral response to COVID-19 vaccination but falling titers emphasize the importance of re-vaccination. <i>Leukemia and Lymphoma</i> , 2022, , 1-5.	0.6	0
2	Reduced intensity allogeneic hematopoietic stem cell transplantation is a safe and effective treatment option in high-risk myeloma patients – a single centre experience. <i>British Journal of Haematology</i> , 2021, 193, 420-423.	1.2	2
3	Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study. <i>British Journal of Haematology</i> , 2021, 193, 750-760.	1.2	8
4	Guidelines on the diagnosis, investigation and initial treatment of myeloma: a British Society for Haematology/UK Myeloma Forum Guideline. <i>British Journal of Haematology</i> , 2021, 193, 245-268.	1.2	24
5	Development of antibody response to SARS-CoV-2 following asymptomatic infection in patients with plasma cell disorders on immunomodulatory therapy. <i>British Journal of Haematology</i> , 2021, 194, 857-861.	1.2	3
6	Serological response to the BNT162b2 mRNA or ChAdOx1 nCoV-19 COVID-19 vaccine after first and second doses in patients with plasma cell disorders: influence of host and disease factors. <i>British Journal of Haematology</i> , 2021, 196, e21.	1.2	11
7	Efficacy and Safety of Carfilzomib at 56mg/m2 with Cyclophosphamide and Dexamethasone (K56Cd) in Newly Diagnosed Multiple Myeloma Patients Followed By ASCT or K56Cd Consolidation: Initial Results of the Phase 2 Cardamon Study. <i>Blood</i> , 2019, 134, 861-861.	0.6	7
8	RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature. <i>Blood</i> , 2018, 132, 2154-2165.	0.6	14